2.
氟维司群联合EGFR-TKI治疗晚期NSCLC的Ⅱ期临床试验
Ongoing phase Ⅱ clinical trials of hormonal therapy in advanced NSCLC
| ClinicalTrials.gov identifier | Patient population | Preselected biomarker | Treatment |
| NSCLC: non-small cell lung cancer. | |||
| NCT01556191 | Stage Ⅲ or Ⅳ NSCLC, postmenopausal women |
EGFR mutation | Gefitinib + fulvestrant vs gefitinib |
| NCT01556191 | Stage Ⅲ or Ⅳ NSCLC, postmenopausal women |
EGFR wildtype | Erlotinib + fulvestrant vs erlotinib |
| NCT00592007 | Stage Ⅲb or Ⅳ NSCLC, both gender | ER and PR expression | Erlotinib + fulvestrant |
| NCT00100854 | Stage Ⅲb or Ⅳ NSCLC, both gender |
None | Erlotinib + Fulvestrant vs erlotinib |
| NCT00932152 | Stage Ⅲb or Ⅳ, postmenopausal women | None | (1) Best supportive care (2) Bevacizumab (3) Fulvestrant + anastrozole (4) Fulvestrant + anastrazole + bevacizumab |